Immunai
New York, New York, United States
How Immunai hit $39.1M revenue with a 194 person team in 2023.
Comprehensively mapping the immune system through the convergence of single-cell biology and artificial intelligence (AI) stands at the forefront of revolutionizing therapeutic discoveries. This innovative approach enables scientists and researchers to delve deeper into the complexities of the immune system, allowing for a more detailed and nuanced understanding of its functioning. By harnessing the precision of single-cell analysis, researchers can observe how individual cells within the immune system respond to various stimuli or conditions, revealing insights that were previously obscured in bulk cell analysis. Integrating AI into this process further enhances the potential for breakthroughs. AI algorithms are capable of processing and analyzing the vast amounts of data generated by single-cell studies swiftly and with remarkable accuracy. This capability not only speeds up the research process but also identifies patterns and relationships that might not be apparent to human researchers. Consequently, AI-driven analysis can predict how different immune cells will react to new therapeutic agents, guiding the development of treatments with higher efficacy and safety profiles. The combination of single-cell biology and AI is transforming the landscape of drug development and patient care. It enables a more targeted approach to therapy, where treatments can be tailored to the specific needs of individuals based on their unique immune system characteristics. This personalized approach holds the promise of significantly improving patient outcomes by ensuring that treatments are more effective and have fewer adverse effects. Moreover, this integrated strategy accelerates the pace of drug development. By providing a clearer understanding of the immune system's intricate mechanisms, it allows for the more efficient identification of viable therapeutic targets. Furthermore, it streamlines the drug development process by enabling more predictive models of drug efficacy and safety, reducing the time and cost associated with bringing new therapies to market. In summary, the synergy of single-cell biology and AI is not just mapping the immune system with unprecedented precision; it is reshaping the future of medicine. By facilitating the discovery of novel therapeutics, accelerating drug development, and ushering in a new era of personalized medicine, it represents a significant leap forward in improving patient outcomes worldwide.
2019
Founded
$39.1M
2023 Revenue
-----
YOY
$295M
Funding
Immunai Revenue
In 2023, Immunai revenue run rate hit $39.1M in revenue.
-
2023
Immunai hit $39.1M in revenue in 2023
-
2019
Immunai launched in 2019 with $0 revenue
Immunai Funding History
No funding has been reported for Immunai yet.
Team
Immunai has 194 total employees.
| DISTRIBUTION | QTY |
|---|---|
| Total team size | 194 |
Founder / CEO
Noam Solomon
Q&A
-
What's your age?
-
-
Favorite online tool?
-
-
Favorite book?
-
-
Favorite CEO?
-
-
Advice for 20 year old self
-
Customers
Churn
Immunai Executives
| Name | Position | Working Email | Personal Email |
|---|---|---|---|
| Noam Solomon | CEO | [email protected] | - |
Immunai Employees
| Name | Position | Working Email | Personal Email |
|---|---|---|---|
| Noam Solomon | CEO | [email protected] | - |
Frequently Asked Questions about Immunai
-
When was Immunai founded?
Immunai was founded in 2019.
-
How much revenue does Immunai generate?
Immunai generates $39.1M in revenue.
-
Who is the CEO of Immunai
The CEO of Immunai is Noam Solomon.
-
How much funding does Immunai have?
Immunai raised $295M.
-
How many employees does Immunai have?
Immunai has 194 employees.
-
Where is Immunai headquarters?
Immunai is headquartered at New York, New York, United States
People Also Viewed
PVcase
Developer of a designing software intended to automate the designing of solar power plants. The company's Autocad plugin-software utilizes proprietary algorithms for analyzing terrain topography automates 3D terrain based solar engineering, enabling designers to perform a number of simulations while evaluating peculiarities of the terrain and select the best place and configuration of a solar power plant.
Placer
Developer of human movement analytics designed for the retail industry. The company's platform generates insights into any physical place and provides actionable location-based insights into the audience and competition, offering retailers with instant access to location insights derived from the foot traffic of millions of consumers, delivering visibility into offline behavior.
Memoryblue
The company primarily operates in the Software industry. Memoryblue was founded in 2002 and is headquartered in Vienna, VA. Similar Companies include HiP B2B and QuotaFactory.
Tidio
TIDIO - AI POWERED CUSTOMER SERVICE PLATFORM Combine AI and human support for excellent customer service
MaxOne
MaxOne is a platform that provides tools and resources for sports teams and coaches to improve performance and communication. It offers features such as video analysis, practice planning, messaging, and player evaluation. The goal of MaxOne is to help teams and coaches streamline their processes and enhance their overall performance.
NoPaperForms Solutions Pvt. Ltd.
Meritto is a platform that helps businesses streamline their application process by eliminating paper forms. It offers online form creation, data collection, and management tools.